CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $115.64M, lower than 95% of all stocks globally
- PositionReturn on equity is -192.2%, lower than 95% of its Biotechnology peers (median -21.7%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
115.64MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-93.37%vs all stocks
Market Capitalization
115.64MUSDvs all stocks (USD)
Enterprise Value
105.34MUSDvs all stocks (USD)
Forward P/E
-8.29xvs Biotechnology peers
Price to Book (MRQ)
43.77xvs Biotechnology peers
Enterprise to EBITDA
-15.82xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-74.42%vs Biotechnology peers
Return on Equity (TTM)
-192.17%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 9, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-6.48MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-5.30MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.53MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-7.82MUSDvs all stocks (USD)
Pre-tax Income
-8.98MUSDFY2025 · Dec 31, 2025Net Income
-8.98MUSDFY2025 · Dec 31, 2025EBIT
-7.82MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-6.66MUSDFY2025 · Dec 31, 2025Research & Development
6.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
1.55MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-8.98MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-3.86MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
5.14MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-8.98MUSDFY2025 · Dec 31, 2025Stock-based Compensation
4.72MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
398.00KUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-27.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
4.47MUSDFY2025 · Dec 31, 2025Shares Outstanding
47.34MSharesUpdated Jul 9, 2026Float Shares
4.28MSharesUpdated Jul 9, 2026Shares Short
347.18KSharesUpdated Jul 9, 2026Short Ratio
1.02daysvs all stocks
Short % of Shares Outstanding
1.61%vs all stocks
% Held by Insiders
69.34%vs all stocks
% Held by Institutions
4.55%vs all stocks
Total Cash (MRQ)
3.08MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.0650USDUpdated Jul 9, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
3.45xvs Biotechnology peers
Book Value per Share (MRQ)
0.0530USDUpdated Jul 9, 2026Total Assets
5.17MUSDvs all stocks (USD)
Total Current Assets
5.17MUSDFY2025 · Dec 31, 2025Total Liabilities
605.00KUSDFY2025 · Dec 31, 2025Total Non-current Assets
0.00USDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
605.00KUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
5.14MUSDFY2025 · Dec 31, 2025Accounts Payable
470.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-99.64MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
4.57MUSDvs all stocks (USD)
52-Week Low
2.01USDUpdated Jul 9, 202652-Week High
48.91USDUpdated Jul 9, 202652-Week Change
-93.37%vs all stocks
50-Day MA
3.96USDUpdated Jul 9, 2026200-Day MA
5.14USDUpdated Jul 9, 2026Avg 10-Day Volume
123.18KSharesUpdated Jul 9, 2026Avg 30-Day Volume
304.64KSharesUpdated Jul 9, 2026Diluted EPS (TTM)
-0.1400USDUpdated Jul 9, 2026Other Income / Expense
-1.16MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -192.2%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -1.92Industry median: -0.22Industry P5: -1.66Peers compared: 261
Price-to-book is 43.77×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 43.77Industry median: 2.97Industry P95: 23.50Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $115.64M, lower than 95% of all stocks globallySignificant
Market cap (USD): 115,642,703Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nibec Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Y-Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cellbion Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
PepGen Inc.
Tier 1ProductionApproval-Gated PipelineRule
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
CVRx, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bonus BioGroup Ltd.
Tier 1ProductionApproval-Gated PipelineRule